Oridonin Inhibits SARS‐CoV‐2 by Targeting Its 3C‐Like Protease
Baisen Zhong, Weiyu Peng, Shan Du, Bingyi Chen, Yajuan Feng, Xinfeng Hu, Qi Lai, Shujie Liu, Zhong‐Wei Zhou, Pengfei Fang, Wu Yan, Feng Gao, Huihao Zhou, Litao Sun
Abstract
Oridonin Inhibits SARS-CoV-2 Oridonin, a natural product extracted from Rabdosia rubescens, possesses a wide range of pharmacological properties, including anti-inflammatory, anti-cancer, anti-microbial, neuroprotection, immunoregulation, etc. In article number 2100124, Baisen Zhong, Litao Sun, and co-workers demonstrate that Oridonin targets the SARS-CoV-2 3CL protease by covalently binding to cysteine145 in its active pocket to exert an anti-SARS-CoV-2 effect, which provides a novel candidate for the treatment of COVID-19.
Topics & Concepts
ProteaseNatural productSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)NeuroprotectionPharmacologyCoronavirus disease 2019 (COVID-19)ChemistryVirologyBiologyEnzymeMedicineBiochemistryDiseaseInfectious disease (medical specialty)PathologyBioactive Natural Diterpenoids ResearchPlant-based Medicinal ResearchComputational Drug Discovery Methods